EGFR and non-small cell lung carcinoma: Furthermore, DCR for mutant EGFR NSCLC cases carrying BIM deletion polymorphism were significantly decreased in comparison with those with BIM wild polymorphism, suggesting that individuals with BIM deletion polymorphism could not obtain benefit more from TKI therapy and it could be used as a genetic biomarker for predicting TKI efficacy in EGFR-mutated NSCLC.